Table 59GRADE evidence profile for SSRIs versus placebo

OutcomesNo. of participants (studies)Quality of the evidence (GRADE)Risk ratios (95% Cls)
Leaving the study early: any reason3137
(25)
⊕⊕⊕○
moderate1
RR 1.11
(0.96 to 1.27)
Leaving the study early: lack of efficacy358
(5)
⊕⊕⊕○
moderate2
RR 0.43
(0.16 to 1.16)
Leaving the study early: due to adverse events1661
(13)
⊕⊕⊕○
moderate1
RR 1.89
(1.23 to 2.89)
Depression: 1. Not achieving success/ remission – patient rated60
(1)
⊕⊕⊕○
moderate3
RR 0.74
(0.46 to 1.18)
Depression: 1. Not achieving success/ remission – observer rated1197
(14)
⊕⊕⊕○
moderate1
RR 0.81
(0.74 to 0.88)
Depression: 2. Non-response – patient rated279
(3)
⊕⊕○○
low2,4
RR 0.73
(0.44 to 1.22)
Depression: 2. Non-response – observer rated1267
(19)
⊕⊕○○
low1,4
RR 0.83
(0.71 to 0.97)
1

Some studies did not clearly report whether they were double blinded.

2

CIs compatible with benefit and no benefit.

3

Sparse data-only one study.

4

I2 > 50%.

From: 8, PHARMACOLOGICAL INTERVENTIONS IN THE TREATMENT AND MANAGEMENT OF DEPRESSION IN ADULTS WITH A CHRONIC PHYSICAL HEALTH PROBLEM

Cover of Depression in Adults with a Chronic Physical Health Problem
Depression in Adults with a Chronic Physical Health Problem: Treatment and Management.
NICE Clinical Guidelines, No. 91.
National Collaborating Centre for Mental Health (UK).
Leicester (UK): British Psychological Society; 2010.
Copyright © 2010, The British Psychological Society & The Royal College of Psychiatrists.

All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. Enquiries in this regard should be directed to the British Psychological Society.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.